Eupraxia Pharmaceuticals (EPRX) Earnings Analysis

Eupraxia Pharmaceuticals (EPRX) has no confirmed upcoming earnings date. Last quarter (2026-03-12) it missed with EPS -0.37 USD vs -0.16 USD est (-131.3%). It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E -6.15.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does EPRX next report earnings?

No confirmed upcoming earnings date is currently scheduled for EPRX. This page updates as the calendar is published.

EPRX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-12-0.37 USD-0.16 USD-131.3%Miss
2025-03-20-0.21 USD-0.18 USD-16.7%Miss
2024-11-07-0.17 USD-0.13072 USD-30%Miss

Beat rate: 0/3 (0%) over reported quarters with consensus data.

EPRX valuation and analyst view

Trailing P/E-6.15
Trailing EPS-0.78495 USD
Price / book2.66
Dividend yield0.00%
Market cap0.22B
Analyst consensusBuy (2 buy / 0 hold / 0 sell)
Avg price target17 USD

Related research pages

Frequently asked questions

When is Eupraxia Pharmaceuticals (EPRX)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for EPRX. This page updates as the calendar is published.

Did EPRX beat earnings last quarter?

In its 2026-03-12 report, EPRX posted EPS of -0.37 USD versus a -0.16 USD estimate — a miss of 131.3%.

What is EPRX's earnings track record?

Over the last 3 reported quarters with consensus data, EPRX beat estimates 0 times (0%).

What is EPRX's current P/E ratio and EPS?

EPRX trades at a trailing P/E of -6.15 on trailing EPS of -0.7849478980200246 USD.

What do analysts rate EPRX?

Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 17 USD.